News
Policy & Recommendations
The European Commission invests in the development of innovative products against respiratory viruses
The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated
News
Policy & Recommendations
EU Working Group on Respiratory Care kick-off meeting
This group will lead the development of a Call to Action to advocate for better access to treatments, in particular COVID- 19.
Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries
Several mucosal vaccines are in development, and consistent methodologies assessing mucosal IgA are crucial for evaluation across clinical trials.
Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8+ T Cell Responses
Immunosenescence, age-related immune dysregulation, reduces immunity upon vaccinations and infections.
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures.
Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review
SARS-CoV-2 viraemia was linked to memory problems and worsened quality of life. Viraemia was associated with signatures denoting dysregulated host responses.
News
Policy & Recommendations
Joint Action on REspiratory Diseases (JARED) launched
A new joint action focusing on tackling chronic respiratory diseases was recently launched. Backed by the EU4Health programme, the 3-year initiative aims to improve lung health across Europe through innovative digital health technologies.
Targeting the SARS-CoV-2 reservoir in long COVID
There are no approved treatments for post-COVID-19 condition, a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people.
